



Spin Column-Based Mitochondrial Isolation: Expanding Biomedical Applications Through Enhanced Purity and Efficiency

Abstract

Mitochondria are central to cellular metabolism, signaling, and apoptosis. Accurate functional and molecular analysis requires high-purity mitochondrial preparations. Traditional isolation methods, such as differential centrifugation and ultracentrifugation, are often time-consuming, yield impure fractions, and show limited reproducibility across diverse tissues. This review evaluates the advantages of spin column-based mitochondrial isolation kit (**Invent Biotechnologies Inc. MP-0-07**) across various sample types—including liver, brain, heart, kidney, cancer tissues, and cell lines—and downstream applications such as proteomics, metabolomics, immunoblotting, and mitochondrial functional assays. The included studies highlight the utility of spin column-based methods for high-throughput, reproducible mitochondrial isolation even from small, frozen, or challenging samples. The enhanced yield and integrity of mitochondria obtained through spin column techniques significantly benefit modern bioanalytical workflows, providing an indispensable tool for mitochondrial research.

Introduction

Mitochondria play multifaceted roles in energy production, ROS regulation, apoptosis, and immune signaling. Isolating intact and functional mitochondria is essential for mechanistic studies, especially as mitochondrial dysfunction is implicated in cancer [20, 53], neurodegeneration [31, 47], cardiovascular disease [19, 43], renal pathology [4, 76], and metabolic disorders [22, 25, 60].

Traditional methods based on differential centrifugation can be hampered by incomplete separation from lysosomes and ER, physical disruption of organelles, and lengthy protocols incompatible with high-throughput workflows [1, 4, 31]. Spin column-based mitochondrial isolation, a more recent innovation, addresses many of these limitations by combining mechanical homogenization with differential centrifugation using only a table top centrifuge. This review discusses its applications and advantages based on over 70 recent publications.

Applications Across Sample Types

Cancer Cell Lines and Tumors

Spin column isolation has been widely used in cancer research. For example, studies of ovarian [5, 20], liver [2], breast [7, 18], and colorectal cancer [21, 75] utilized mitochondrial isolates for analyzing apoptotic signaling, mitochondrial DNA release, and mitophagy. These assays, such as mitochondrial membrane potential measurement, Western blotting for cytochrome c or BAX translocation, and Seahorse metabolic flux analyses, depend on mitochondria of high purity and intact function—attributes facilitated by spin columns.

The importance of mitochondrial metabolism in drug resistance is evident in ovarian cancer studies exploring cisplatin resistance mediated by mitochondrial biogenesis [6, 22] and mitophagy-related HK2 localization [28].

Neural and Brain Tissue

Neurodegenerative models often require brain mitochondria isolation for proteomics or ultrastructural analysis. Spin column methods have enabled the study of mitochondrial morphology in Parkinson's [31, 47], neuroinflammation [71, 74], and ischemia models [35, 40]. Atomic force microscopy [3], TEM, and mitochondrial respiration assessments rely on minimally disrupted mitochondria, achievable only through gentle isolation protocols such as spin column kits.

Liver and Kidney Tissue

In hepatic models, spin column-isolated mitochondria have been central to studying mitochondrial permeability transition pores (mPTP), mitophagy, and oxidative stress, as in acetaminophen-induced liver injury [52], NASH [27], and ischemia-reperfusion [23]. Kidney research—including diabetic nephropathy [4, 50, 76] and acute kidney injury [8]—utilized purified mitochondria to assess mitochondrial SOD2 acetylation, HK2 translocation, and metabolic rewiring.

Cardiac and Skeletal Muscle

Cardiomyocyte and vascular smooth muscle models benefit from high-yield mitochondrial isolates when evaluating Drp1-regulated apoptosis [24, 56], ischemic injury [19, 46], and inflammation [43, 61]. Spin columns minimize cytosolic contamination, allowing accurate measurement of mitochondrial-specific proteins and ROS levels in myocardial injury studies [43, 62].

Intestinal, Lung, and Immune Tissues

Spin column-isolated mitochondria have enabled detailed exploration of mitochondrial quality control in sepsis [64, 65], pulmonary fibrosis [72], and gut barrier integrity [16, 23]. Immuno-metabolic studies in macrophages and endothelial cells used mitochondria purified via spin columns for mass spectrometry and mitophagy detection [19, 42].

Stem Cells and Engineered Mitochondria

Recent advancements using engineered or nanoparticle-loaded mitochondria for therapy or delivery in models of ocular disease [70], skeletal muscle dysfunction [46], and brain injury [72] rely on mitochondria with preserved membrane integrity and function, which are better retained through spin column-based isolation.

Downstream Assays Enhanced by Spin Column-Based Isolation

- **Western Blotting and Subcellular Fractionation:** High-purity mitochondrial fractions reduce cross-contamination with nuclear or cytosolic markers, increasing the reliability of protein quantification [10, 52, 62].
- **Functional Assays:** Studies assessing mitochondrial membrane potential, oxygen consumption rate (OCR), and ATP production require mitochondria with intact bioenergetics [31, 43, 65].
- **Mass Spectrometry and Proteomics:** Clean mitochondrial preparations are essential for meaningful MS-based quantification of mitochondrial proteomes [50, 53, 76].
- **Imaging and Morphological Analysis:** Mitochondrial ultrastructure analysis via TEM or AFM benefits from minimal processing damage [3, 31, 47].

Advantages Over Traditional Methods

- **Time Efficiency and Reproducibility:** Spin column methods standardize isolation steps and reduce processing time from hours to under 40 minutes, improving reproducibility across operators [2, 21, 52].
- **Small Sample Input:** These methods are particularly effective for small tissue biopsies or limited cell numbers, essential for clinical and preclinical research [16, 27, 31].
- **Preservation of Organelle Function:** Gentle handling during column filtration reduces mitochondrial rupture and loss of membrane potential, as observed in bioenergetic studies [6, 19, 70].
- **Broad Applicability:** Consistent performance across sample types—including frozen tissues, primary cells, and tumor xenografts—expands the utility of spin column kits for translational research [5, 28, 75].

Conclusion

Spin column-based mitochondrial isolation has transformed experimental capabilities in mitochondrial research. Its rapidity, compatibility with diverse tissues, and improved yield of intact organelles make it the preferred choice for functional assays, proteomics, and therapeutic research. As studies continue to link mitochondrial dysfunction to disease, standardized high-purity isolation methods will be foundational for reproducible and scalable biomedical discovery.

References

1. Gou R, et al. Resveratrol suppresses oxidized low-density lipoprotein-induced macrophage apoptosis through inhibition of intracellular reactive oxygen species generation, lox-1 and the p38 MAPK pathway. *Cell Physiol Biochem*. 2014;34:603–616.
2. Hu H, et al. Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. *Hepatology*. 2016.
3. Gao G, et al. Morphological analysis of mitochondria for evaluating the toxicity of α -synuclein in transgenic mice and isolated preparations by atomic force microscopy. *Biomed Pharmacother*. 2017.

4. Zhang L, et al. PGC-1 α ameliorates kidney fibrosis in mice with diabetic kidney disease through an antioxidative mechanism. *Mol Med Rep.* 2018.
5. Wu Y, et al. SIRT3 aggravates metformin-induced energy stress and apoptosis in ovarian cancer cells. *Exp Cell Res.* 2018.
6. Shen L, et al. PGC1 α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis. *Int J Oncol.* 2018.
7. Han W, et al. ZIC1 acts as a tumor suppressor in breast cancer by targeting survivin. *Int J Oncol.* 2018.
8. Ouyang J, et al. SIRT3 inactivation promotes acute kidney injury through elevated acetylation of SOD2 and p53. *J Surg Res.* 2019;233:221–230.
9. Zhou K, et al. VDAC2 interacts with PFKP to regulate glucose metabolism and phenotypic reprogramming of glioma stem cells. *Cell Death Dis.* 2018;9(10):988.
10. Xue YN, et al. Zinc and p53 disrupt mitochondrial binding of HK2 by phosphorylating VDAC1. *Exp Cell Res.* 2018.
11. Chen XY, et al. Isoliquiritigenin induces mitochondrial dysfunction and apoptosis by inhibiting mitoNEET in a ROS-dependent manner in A375 human melanoma cells. *Oxid Med Cell Longev.* 2019.
12. Ma J, et al. Functional prediction and characterization of Dip2 gene in mice. *Cell Biol Int.* 2019.
13. Cai M, et al. Hypoxia-induced mitochondrial translocation of DNMI1L increases mitochondrial fission and triggers mPTP opening in HCC cells via activation of HK2. *Oncol Rep.* 2019.
14. Guo Z, et al. Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1. *Eur J Pharm Sci.* 2019;105:105.
15. Yue J, et al. In situ and ex situ surface-enhanced Raman spectroscopy (SERS) analysis of cell mitochondria. *J Raman Spectrosc.* 2019.
16. Duan C, et al. Activated Drp1-mediated mitochondrial ROS influence the gut microbiome and intestinal barrier after hemorrhagic shock. *Aging (Albany NY).* 2020;12(2):1397.
17. Duan C, et al. Drp1 regulates mitochondrial dysfunction and dysregulated metabolism in ischemic injury via Clec16a-, BAX-, and GSH-pathways. *Cell Death Dis.* 2020;11(4):1–19.
18. Han W, et al. Roles of eIF3m in the tumorigenesis of triple-negative breast cancer. *Cancer Cell Int.* 2020;20(1):1–16.
19. Fei Q, et al. Metformin protects against ischaemic myocardial injury by alleviating autophagy-ROS-NLRP3-mediated inflammatory response in macrophages. *J Mol Cell Cardiol.* 2020.
20. Hu X, et al. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy. *Biomed Pharmacother.* 2020;129:110397.
21. Lu D, et al. ACADSB regulates ferroptosis and affects the migration, invasion and proliferation of colorectal cancer cells. *Cell Biol Int.* 2020.
22. Deng X, et al. The Nrf2/PGC1 α pathway regulates antioxidant and proteasomal activity to alter cisplatin sensitivity in ovarian cancer. *Oxid Med Cell Longev.* 2020.
23. Huang J, et al. Inhibition of Drp1 SUMOylation by ALR protects the liver from ischemia-reperfusion injury. *Cell Death Differ.* 2020.

24. Zhao L, et al. Polyphyllin VII induces mitochondrial apoptosis by regulating the PP2A/AKT/DRP1 signaling axis in human ovarian cancer. *Oncol Rep.* 2020.
25. Luo Q, et al. OTUD1 activates caspase-independent and caspase-dependent apoptosis by promoting AIF nuclear translocation and MCL1 degradation. *Adv Sci.* 2021;2002874.
26. She H, et al. Protective effects of dexmedetomidine on the vascular endothelial barrier function by inhibiting mitochondrial fission via ER/mitochondria contact. *Front Cell Dev Biol.* 2021;9.
27. Zhou J, et al. A rapid juvenile murine model of nonalcoholic steatohepatitis (NASH): chronic intermittent hypoxia exacerbates Western diet-induced NASH. *Life Sci.* 2021;119403.
28. Yu S, et al. Mutation in the UBA domain of p62 changes sensitivity to cisplatin by increasing HK2 localisation on mitochondria in ovarian cancer cells. *Int J Mol Sci.* 2021;22(8):3983.
29. Wu X, et al. 2-Undecanone protects against fine particle-induced kidney inflammation via inducing mitophagy. *J Agric Food Chem.* 2021.
30. Zhao L, et al. Bhlhe40/Sirt1 axis-regulated mitophagy in all-trans retinoic acid-induced spina bifida aperta. *Front Cell Dev Biol.* 2021;9:1025.
31. Feng ST, et al. Inhibition of dynamin-related protein 1 ameliorates mitochondrial ultrastructure via PINK1 and Parkin in Parkinson's disease. *Eur J Pharmacol.* 2021;174262.
32. Wang Y, et al. Pentoxifylline enhances antioxidative capability and mitochondrial biogenesis in aging mice via Nrf2 and PGC-1 α through cAMP-CREB pathway. *Oxid Med Cell Longev.* 2021.
33. Duan C, et al. Mitochondrial Drp1 induces mPTP opening after hypoxia through BAX-PiC and LRRK2-HK2. *Cell Death Dis.* 2021;12(11):1–10.
34. Li T, et al. African swine fever virus pE199L induces mitochondrial-dependent apoptosis. *Viruses.* 2021;13(11):2240.
35. Meng H, et al. HtrA2/Omi regulates adaptive mitochondrial reprogramming after ischemia/reperfusion injury via UCP2-SIRT3-PGC1 axis. *Hum Cell.* 2021.
36. Li X, et al. SARS-CoV-2 ORF10 suppresses antiviral innate immune response by degrading MAVS through mitophagy. *Cell Mol Immunol.* 2021.
37. Yan X, et al. Autophagy-induced HDAC6 activity regulates mitochondrial energy metabolism via β -catenin/COUP-TFII axis in HCC cells. *Front Oncol.* 2021;4275.
38. Xiao L, et al. TRAP1 suppresses OSCC progression by reducing OXPHOS metabolism of CAFs. *BMC Cancer.* 2021;21(1):1–14.
39. Cheng M, et al. Mitochondrial PHB2/OMA1/DELE1 pathway cooperates with ER stress in ovarian cancer chemotherapy. *Int J Mol Sci.* 2022;23(3):1320.
40. Liu J, et al. Sevoflurane neurotoxicity in neonatal mice links to GSK3 β /Drp1 mitochondrial fission and apoptosis. *Free Radic Biol Med.* 2022.
41. Huang F, et al. PSL-LCCL: a resource for subcellular protein localization in SK_HEP1 cells. *Database.* 2022.
42. He XT, et al. Molybdenum regulates immunometabolism and mitochondrial function in wound healing. *Biomaterials.* 2022;121439.
43. Zhao M, et al. Gut microbiota metabolite accelerates cardiac hypertrophy by reducing FA oxidation. *Nat Commun.* 2022;13(1):1–18.

44. Hu W, et al. Angiotensin-(1–7) promotes mitochondrial translocation of telomerase via TOM20. *Arch Biochem Biophys*. 2022;109218.
45. Xu Y, et al. CD137 signal mediates cardiac ischemia–reperfusion injury via necrosis regulation. *J Cardiovasc Transl Res*. 2022.
46. Li B, et al. FGF21 inhibits Drp1 activation to alleviate muscle ischemia/reperfusion injury. *Lab Invest*. 2022.
47. Wang XL, et al. Mangiferin inhibits Drp1 and aberrant mitophagic proteins in Parkinson's disease. *Phytomedicine*. 2022;154281.
48. Wu T, et al. HSPD1 translocation induced by *Streptococcus suis* mediates apoptosis and BBB loss. *Cells*. 2022;11(13):2071.
49. An W, et al. ALR ubiquitination imbalance accelerates NASH to HCC. Unpublished 2022.
50. Wang M, et al. Crotonylome analysis reveals Shengkang injection mechanisms in diabetic nephropathy. *Oxid Med Cell Longev*. 2022.
51. Wang Y, et al. Engineered mitochondria suppress mitochondrial heterogeneity and disease phenotypes. 2022.
52. Zhu Y, et al. NEDD4-1 protects against acetaminophen liver injury by degrading VDAC1. *Acta Pharm Sin B*. 2023.
53. Edwards-Hicks J, et al. Phosphoinositide acyl chain saturation drives CD8+ T cell signaling. *Nat Immunol*. 2023.
54. Yin M, et al. Raddeanin A enhances mitochondrial DNA–cGAS/STING immunity. *Adv Sci*. 2023.
55. Dou Y, et al. Presequence protease reverses mitochondria-specific A β -induced mitophagy. *FASEB J*. 2023;37(5):e22890.
56. Li CQ, et al. Mdivi-1 alleviates atherosclerosis via DRP1 inhibition. *J Transl Med*. 2023;21(1):1–17.
57. Zhang M, et al. PCSK9 promotes EC pyroptosis by Smac mitochondrial translocation. *Cell Mol Biol Lett*. 2024;29(1):47.
58. Duan C, et al. Activated Drp1 forms ER-mitochondrial contacts via Shrm4-actin bundling. *Adv Sci*. 2023;2304885.
59. Wu K, et al. Mitophagy improves cognitive dysfunction in diabetic mice. *Mol Cell Endocrinol*. 2023;112109.
60. Zhang G, et al. MiR-326 triggers Th17/Treg imbalance and hepatocyte pyroptosis. *Ann Hepatol*. 2023;101183.
61. Song JX, et al. Hydrogen attenuates CIH-induced cardiac hypertrophy via iron metabolism regulation. *Curr Issues Mol Biol*. 2023;45(12):10193–10210.
62. Wei C, et al. SIRT5 lysine demalonylation of GSTP1 suppresses cardiomyocyte pyroptosis. *Int J Biol Sci*. 2024;20(2):585.
63. Zhang J, et al. NSD2 modulates Drp1-mediated fission in renal fibrosis via STAT1 methylation. *Pharmacol Res*. 2024;107051.
64. Hou D, et al. Notoginsenoside R1 improves microvascular function in sepsis by correcting Drp1 imbalance. *Pharm Biol*. 2024;62(1):250–260.
65. Hou D, et al. Curcumin improves mitochondrial dynamics and energy in sepsis via SIRT1-DRP1/PGC-1 α . *Heliyon*. 2024.
66. Bi YY, et al. Nanoparticles targeting mutant p53 overcome chemoresistance in NSCLC. *Nat Commun*. 2024;15(1):1–18.

67. Zhang T, et al. G6PD maintains VSMC phenotype and promotes neointimal hyperplasia by inhibiting VDAC1-Bax apoptosis. *Cell Mol Biol Lett*. 2024;29(1):47.
68. Zhao H, et al. CPT1C promotes tumor progression by enhancing energy supply and G1/S transition. *Cell Commun Signal*. 2024;22(1):1–17.
69. Li X, et al. Melatonin alleviates inflammation-induced mitochondrial dysfunction via METTL3/LINC01444/HSPD1 axis. *Fundam Res*. 2024.
70. Wang Y, et al. Nanoengineered mitochondria enable therapy of ocular mitochondrial disease. *Acta Pharm Sin B*. 2024.
71. Zhao X, et al. Succinylation induces microglial senescence via mitochondrial energy metabolism alteration. *J Neuroinflammation*. 2024;21:296.
72. Wang Y, et al. Mitophagy-enhanced nanoparticle mitochondria restore mitochondrial pool in pulmonary fibrosis. *ACS Nano*. 2024.
73. Yuan Z, et al. ApoM regulates mitophagy-apoptosis balance during neural tube closure via Nnt mRNA stability. 2024.
74. Zhao X, et al. Succinylation promotes senescence in microglia by altering mitochondrial energy metabolism. *J Neuroinflammation*. 2024;21(1):296.
75. Yao H, et al. Gut microbiota-mediated hsa_circ_0126925 targets BCAT2 to exacerbate colorectal cancer. *Mol Cancer Res*. 2025;OF1–OF17.
76. Liu Y, et al. Combining mitochondrial proteomes and Mendelian randomization to identify therapeutic targets in diabetic nephropathy. *Ren Fail*. 2025;47(1):2473669.